• Ticker

    Advertisement Find a Broker - Visit the DailyFinance Broker Center
DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$3.80 -$0.25 (-6.17%)

REAL-TIME: Last trade at

Compugen Ltd. (USA)

NASDAQ:CGEN

Jump to this page for:

Related Resources

7 Stocks Under $10 Soaring Higher

5/24/2012 by TheStreet.com

Tel Aviv Stock Exchange and Nasdaq co-host a conference

5/17/2012 by Theflyonthewall.com

Compugen Ltd. Reports First Quarter 2012 Financial Results

5/1/2012 by PharmiWeb.com - UK

Compugen reports Q1 EPS (12c), 1Q11 EPS 6c

5/1/2012 by Theflyonthewall.com

Compugen Ltd. Reports First Quarter 2012 Financial Results

5/1/2012 by Business Wire

Compugen announces further results for CGEN-15001

4/24/2012 by Theflyonthewall.com

Compugen Announces Initial Validation Results for Two Novel Immunomodulatory Proteins and Further Results for CGEN-15001

4/24/2012 by Business Wire

Dr. Mary Haak-Frendscho, Chairperson of Compugen’s US Subsidiary, to Give Keynote Address at China Pharmaceutical R&D Summit

4/23/2012 by PharmiWeb.com - UK

Dr. Mary Haak-Frendscho, Chairperson of Compugen’s US Subsidiary, to Give Keynote Address at China Pharmaceutical R&D Summit

4/23/2012 by Business Wire

Compugen Establishes Operations in California for Development of Monoclonal Antibody Drug Candidates

3/28/2012 by PharmiWeb.com - UK

Compugen establishes operations in California for drug candidate development

3/28/2012 by Theflyonthewall.com

Compugen Establishes Operations in California for Development of Monoclonal Antibody Drug Candidates

3/28/2012 by Business Wire

Martin Gerstel reports 6.4% passive stake in Compugen

3/12/2012 by Theflyonthewall.com

Compugen falls 3.9%

2/27/2012 by Theflyonthewall.com

Compugen Presents Prediction Based Discovery Strategy at “Targets and Strategies for Drug Discovery” Conference

2/27/2012 by Business Wire

Compugen Ltd. Reports Fourth Quarter and Calendar 2011 Financial Results

2/7/2012 by PharmiWeb.com - UK

Compugen reports Q4 EPS (13c) vs. consensus (10c) (One est)

2/7/2012 by Theflyonthewall.com

Compugen says no revenues recorded for Q4

2/7/2012 by Theflyonthewall.com

Compugen Ltd. Reports Fourth Quarter and Calendar 2011 Financial Results

2/7/2012 by Business Wire

Compugen to Present at the BIO CEO & Investor Conference 2012

2/6/2012 by Business Wire

Compugen announces CGEN-15001T results demonstrating potential

2/2/2012 by Theflyonthewall.com

Compugen Cancer Target Results Demonstrate Significant Potential for Cancer Immunotherapy

2/2/2012 by Business Wire

Compugen presents three product candidates for treatment of autoimmune diseases

1/30/2012 by Theflyonthewall.com

Compugen Presents Three Product Candidates for Treatment of Autoimmune Diseases at the Immunotherapeutics & Immunomonitoring Conference

1/30/2012 by Business Wire

Compugen gets $8M investment toward monoclonal antibody program expansion

12/20/2011 by Theflyonthewall.com

Compugen to Broaden and Accelerate Monoclonal Antibody Program for Oncology and Immunology

12/20/2011 by Business Wire

BioLineRx to Develop and Commercialize Novel Peptide Drug Candidates Discovered by Compugen

12/13/2011 by Business Wire

Compugen presents predictive drug target discovery platform at Euro conference

11/30/2011 by Theflyonthewall.com

Compugen Presents Predictive Drug Target Discovery Platform at European Antibody Conference

11/30/2011 by Business Wire

Compugen, DiscoveRx form collaborative partnership

11/29/2011 by Theflyonthewall.com

Compugen and DiscoveRx® Form Collaboration to Commercialize Novel Peptide Ligands for GPCR Drug Targets

11/29/2011 by Business Wire

Compugen reports Q3 EPS (10c) vs. consensus (9c) (One estimate)

11/8/2011 by Theflyonthewall.com

Compugen Reports Third Quarter 2011 Financial Results

11/8/2011 by Business Wire

Compugen's CGEN-15001 pre-clinical data presented at Immune conference

10/25/2011 by Theflyonthewall.com

Compugen's CGEN-15001 Pre-Clinical Data Presented at International Conference on Immune Tolerance

10/25/2011 by Business Wire

Compugen Third Quarter 2011 Conference Call Scheduled for Tuesday, November 8, 2011 at 10:00 AM EST

10/24/2011 by Business Wire

Pulmonary Fibrosis Foundation funds studies for Compugen drug candidate

10/12/2011 by Theflyonthewall.com

Pulmonary Fibrosis Foundation to Fund Further Therapeutic Evaluation Studies for Compugen-Discovered Drug Candidate

10/12/2011 by Business Wire

Compugen announces validation of two immune system modulating drug candidates

9/13/2011 by Theflyonthewall.com

Compugen Announces Validation of Two Immune System Modulating Drug Candidates

9/13/2011 by Business Wire
See More Articles...